Remit - To appraise the clinical and cost effectiveness of trastuzumab emtansine within its marketing authorisation for treating human epidermal growth factor receptor (HER2) positive breast cancer in the adjuvant setting
Status In progress
Process STA 2018
ID number 1516

Provisional Schedule

Expected publication 10 June 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Roche
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care and Breast Cancer Now
Professional groups Association of Breast Surgery
  Cancer Research UK
  Royal College of PhysicianRoyal College of Radiologists
  UK Breast Cancer Group


Comparator companies Merck Sharp & Dohme
General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
24 March 2020 Committee meeting: 1
22 July 2019 Invitation to participate
10 May 2019 In progress, Referred 13 February 2019
21 March 2019 - 18 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance